Prostate Neoplasm Clinical Trial
Official title:
Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer
The purpose of this study is to look at the effects of a 10-week stress management in-person group program. The program will study emotions, stress, and stress management techniques (such as relaxation and coping techniques) on quality of life, distress, depression, and physical health in Spanish- speaking, Hispanic/Latino men diagnosed with Prostate Cancer (PC).
This 5-year study evaluates the effects of a 10-week group-based linguistically translated and culturally adapted cognitive-behavioral stress and self-management (C-CBSM) intervention on symptom burden and health related quality of life (HRQoL) in Hispanic men treated for localized prostate cancer (PC). About 80% PC cases are diagnosed as early disease and have a 5- and 10-year survival rate of almost 100% and 99%, respectively.1 Most patients receive active treatment (~70%) leading to prolonged treatment-related side effects and dysfunction persisting well beyond primary treatment. Survival is offset by chronic side effects such as sexual and urinary dysfunction, pain and fatigue that can lead to poor psychosocial functioning, impaired intimacy and social functioning, and masculinity concerns. Hispanic PC survivors report lower physical and social functioning, poorer emotional well-being and greater sexual and urinary dysfunction, even after accounting for SES and disease severity. These sequelae can lead to elevated glucocorticoid release and inflammatory cytokines that have a direct effect on these symptoms and can interfere with physiological pathways necessary for recovery of sexual and urinary functioning. We have shown that CBSM reduces symptom burden and improves HRQoL in bilingual Hispanic PC survivors. In a pilot we showed that a linguistic translation of CBSM with attention to sociocultural processes improved symptom burden and HRQoL in Spanish monolingual PC survivors. We have also shown that CBSM is associated with reduced glucocorticoid resistance and inflammatory gene expression pathways in circulating leukocytes among breast cancer survivors. We propose to (a) deliver a culturally adapted C-CBSM intervention in Spanish that places greater emphasis on salient sociocultural determinants of symptom burden and HRQoL in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo), (b) incorporate a neuroimmune model of symptom regulation and management, and (c) test the efficacy of C-CBSM, relative to standard non-culturally adapted CBSM, in two diverse Hispanic communities (Chicago & Miami). We will test our aims in 200 Hispanic men post-treatment for localized PC with elevated symptom burden in a 2 x 4 randomized design with condition (C-CSBM vs. CBSM) as the between groups factors, and time (baseline, post-intervention & 6- and 12-months post intervention) as the within groups factor. Our Primary Aim is to determine whether randomization to C-CBSM, relative to standard CBSM, is associated with reduced symptom burden and improved HRQoL. Our Secondary Aims evaluate whether C-CBSM leads to greater improvements in the intervention targets (e.g., stress management, psychological distress & interpersonal disruption), and physiologic adaptation (i.e., glucocorticoid receptor sensitivity & inflammatory gene expression). We will also evaluate psychosocial and physiological mechanisms as mediators of C-CBSM's effects on our primary outcomes. We also explore several moderators (e.g., SES, acculturation, treatment, Hispanic origin) of C-CBSM's effect on primary outcomes and the effects of C-CBSM on cardiometabolic health (e.g., lipids, fasting glucose) via reduced inflammation. Primary Aim 1: Determine whether participation in C-CBSM is associated with significantly greater reductions in symptom burden and improvements in HRQoL relative to participation in CBSM. Secondary Aims: Aim 2: Determine whether participation in C-CBSM is associated with significantly greater improvements in intervention targets (i.e., improved stress management, and reduced psychological distress and interpersonal disruption) relative to participation in the CBSM condition. Aim 3: Determine whether participation in C-CBSM is associated with significantly greater activation of leukocyte glucocorticoid receptor and less inflammatory gene expression profiles relative to CBSM. Aim 4: Determine whether C-CBSM related improvements in symptom burden and HRQoL are mediated by improvements in intervention targets and gene expression profiles. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06315595 -
Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion
|
||
Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
Completed |
NCT00255125 -
Role of Soy Supplementation in Prostate Cancer Development
|
Phase 3 | |
Terminated |
NCT02809690 -
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
|
Phase 1 | |
Completed |
NCT06020287 -
The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
|
||
Recruiting |
NCT03572946 -
Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection
|
N/A | |
Recruiting |
NCT05137561 -
Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy
|
N/A | |
Recruiting |
NCT04792138 -
Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
|
||
Completed |
NCT03702439 -
Prostate Cancer Screening Trial Using Imaging
|
||
Completed |
NCT04852224 -
Strength, Aging, and Memory in Prostate Cancer
|
||
Completed |
NCT01240551 -
F-18 Sodium Fluoride in Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06430411 -
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
|
||
Recruiting |
NCT02436122 -
Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT03493945 -
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
|
Phase 1/Phase 2 | |
Completed |
NCT04376008 -
A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia
|
N/A | |
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06292897 -
Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
|
||
Recruiting |
NCT03819751 -
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
|
N/A | |
Not yet recruiting |
NCT05460312 -
Protein Kinase A in Prostate Cancer Tissue.
|
||
Completed |
NCT00005916 -
PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
|
Phase 2 |